Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00304200

Temodar and Sutent as Therapy for Melanoma

Temodar and Sutent as Therapy for Patients With Malignant Melanoma, a Phase I/II Study

Sponsor: Northern California Melanoma Center

Conditions Metastatic Malignant Melanoma

Updated 5 times since 2017 Last updated: Feb 3, 2009 Started: Mar 31, 2006 Primary completion: Oct 31, 2007 Completion: Jan 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Funding was inadequate to continue; Companies requested closure.

Other Metastatic Malignant Melanoma trials with similar outcome

NCT01705392 · Phase PHASE2 · Feb 2017

Browse all Metastatic Malignant Melanoma trials

This PHASE1/PHASE2 trial investigates Metastatic Malignant Melanoma and is currently terminated or withdrawn. Northern California Melanoma Center leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1_PHASE2

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Northern California Melanoma Center
Pfizer
Schering-Plough

Data source: Northern California Melanoma Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Francisco, United States